Indivior’s (INDV) Buy Rating Reiterated at Jefferies Financial Group

Jefferies Financial Group restated their buy rating on shares of Indivior (LON:INDV) in a report released on Tuesday morning, MarketBeat Ratings reports. Jefferies Financial Group currently has a GBX 1,800 ($22.50) target price on the specialty pharmaceutical company’s stock.

Separately, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a GBX 1,500 ($18.75) price target on shares of Indivior in a research report on Thursday, September 5th.

Indivior Price Performance

Shares of LON:INDV opened at GBX 913.50 ($11.42) on Tuesday. The company’s fifty day moving average is GBX 775.71 and its two-hundred day moving average is GBX 917.47. The company has a market cap of £1.17 billion, a P/E ratio of -1,141.88, a price-to-earnings-growth ratio of -5.57 and a beta of 0.19. Indivior has a 12-month low of GBX 554.50 ($6.93) and a 12-month high of GBX 1,770 ($22.12). The company has a quick ratio of 1.52, a current ratio of 0.85 and a debt-to-equity ratio of 2,790.00.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.